Can We Give a Targeted Drug Instead of Chemotherapy in Early-Stage Breast Cancer?

Presented at ESMO 2017, in the metastatic setting the success of targeted therapy without chemotherapy was demonstrated by the MONARCH-3 study. Following it, the LORELEI study investigating the efficacy of targeted therapy in patients with early-stage hormone-positive, Her2 receptor-negative breast cancer attracted attention.
A Solution Is on the Way for Resistance to Hormone Therapy in Breast Cancer
Cell growth signaling pathways include one in which the protein called phosphatidylinositol 3 kinase (PI3P) plays a role. It is important in transmitting signals coming from outside the cell. It also forms the main hub of the pathway we call Akt/mTOR, which is activated after signals from outside the cell. Among patients with hormone receptors, %30-40 may have a mutation in the gene encoding this protein. Alteration of PI3P is also the most common genetic change in the development of resistance to hormonal therapies . The first agent developed directly against this pathway is taselisib. In early-stage breast cancer, a clinical study evaluated the benefit of combining taselisib, one of the drugs directly suppressing this pathway, with one of our hormone-suppressing drugs, letrozole. This clinical trial evaluating the combination was presented at the European Cancer Congress.
You May Be Interested In:
The LORELEI study included 22 countries, 85 centers and a total of 334 patients. Postmenopausal patients with early-stage (stage 1-3), hormone-positive, Her2 receptor-negative disease were enrolled. These patients were evaluated for genetic alterations in the PI3P pathway.
Among these patients, those carrying a PI3P mutation who received dual treatment had a treatment benefit rate of %56, compared with %39 in those receiving hormone-suppressing therapy alone. In the patient group without a mutation in the PI3P gene, the dual treatment also provided an additional %11 benefit.
Hormone-suppressing therapies produce a slower treatment response. With hormone-suppressing treatments given before surgery, the average response time is between 4-6 months. Adding the targeted agent taselisib to the hormone-suppressing drug letrozole resulted in an average response time of 4 months.
Common problems associated with adding taselisib included diarrhea, nausea, rash and elevated blood glucose; the manageability of these side effects made treatment easier. This is the first study using the targeted drug taselisib with hormone-suppressing therapy in early-stage hormone receptor (+), HER2 (-) patients. Its encouraging results indicate that oncology is rapidly moving toward personalized treatment rather than a general treatment approach.
We will continue to follow the detailed study results when they are published for you.
Sources
ESMO 2017. Abstract LBA10_PR
Was this article helpful?
Your feedback helps us improve our content.




Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.